Consensus Statements of the American College of Veterinary Internal Medicine (ACVIM) provide the veterinary community with uptodate information on the pathophysiology, diagnosis, and treatment of clinically important animal diseases. The ACVIM Board of Regents oversees selection of relevant topics, identification of panel members with the expertise to draft the statements, and other aspects of assuring the integrity of the process.
daily or every-other-day small molecule inhibitor treatment also increases the risk of exposure to clients.
Handling of cytotoxic drugs has been classified as an occupational health hazard according to a National Institute for Occupational Safety and Health (NIOSH) alert, first published in 2004 and most recently updated in 2016. 4 Such drugs are carcinogenic, mutagenic, teratogenic, abortifacient, and increase the risk of stillbirth. [5] [6] [7] [8] Some of this information has been derived from in vitro studies, animal studies, and from studies in pregnant women receiving chemotherapy for their own malignancies, but adverse effects still might be seen at lower levels of exposure. Compared to intermittent high-dose exposure, chronic low levels of cytotoxic chemotherapy exposure actually may have increased risk, because cytotoxic effects are less likely to occur with similar mutagenic effects. 9 Veterinary small molecule inhibitors, although often not considered "classical" chemotherapy agents, carry similar risks, according to package inserts (https:// www.zoetisus.com/products/dogs/palladia/index.aspx). Current targets are associated with angiogenesis, and treatment with these agents could harm a growing fetus. They should be handled as other cytotoxic drugs.
Human healthcare workers (eg, pharmacy employees, nurses) handling chemotherapeutics have been found to have variably increased chromosomal aberrations compared to the general population, [9] [10] [11] [12] [13] [14] [15] [16] as well as urinary excretion of these drugs or their metabolites, 17, 18 which could lead to similar reproductive complications found in cancer patients treated with cytotoxic drugs. [19] [20] [21] [22] [23] In fact, some large studies 5 and a meta-analysis 24 have shown an incremental increased risk of infertility and early pregnancy loss with occupational exposure to chemotherapeutics. Chromosome changes appear to be exposure-and drug-dependent, with high-volume practice and alkylators being associated with the most abnormalities. 10 Additionally, the chance of developing some cancers might be increased. 21, 23, 25 As a caveat, most of the studies included in the meta-analysis were performed before the widespread use of closed-system transfer devices (CSTD). Various methods used to detect abnormalities, lifestyle factors, amount of exposure to cytotoxic drugs, and variable use of safety measures impact the usefulness of these studies in attributing causation to these health risks. The addition of protective measures such as biologic safety cabinets (BSCs), CSTDs, and personal protective equipment (PPE) markedly decreases, but does not always eliminate, evidence of drug contamination. 16, 26, 27 In veterinary medicine, several studies have been performed to investigate occupational risk in reproductive outcomes and cancer development. However, chemotherapy use and exposure have not been specifically investigated related to these outcomes. A 1998 study of 3000 female veterinary graduates showed both a decreased risk of preterm delivery and a decreased risk for small-for-gestational age births compared to the general population. 28 In a review of several studies examining the cause of death in veterinarians, an increased risk was found for the development of multiple myeloma (6 cases out of 12 000), and a decreased risk for lung cancer, but overall there was a similar risk of cancer as in the general population and no conclusion about specific occupational exposures could be made. 29 Reportedly, 71% of veterinary practices in the United Kingdom use cytotoxic drugs, indicating that practitioners do need to be aware of the use of protective procedures when using chemotherapeutics. 30 In a 2009 survey of 93 practices in Hampshire, 31 half of which used cytotoxic drugs, 100% reported compliance with staff training, exclusion of pregnant workers, waste management, and instructions to clients about precautions. However, none had a designated BSC, and only 82% used PPE. In a survey of Canadian veterinary practice, 30% of general practitioners and 22% of academic veterinarians reported using chemotherapeutics. 32 Mixed or small animal practitioners made up 91% of the private practice population and equine practitioners 8.6%. In 8% of general practice veterinarians, accidental exposures to cytotoxic drugs were reported. Academic veterinarians using chemotherapeutics were mostly small animal or mixed practitioners (47%), although a larger proportion of equine veterinarians using chemotherapeutics was found in academia (35%). No accidental exposures were reported in this population. In the Netherlands, a 2006 study found frequent contamination of the veterinary practice environment, including gloves of personnel administering chemotherapy, surfaces of preparation and administration areas, floors, and door handles. 33 In a review of an American veterinary teaching hospital in 2010, surface contamination was found in 10% of swabs within the preparation area only, and 60%-70% compliance with safety procedures regarding the use of PPE was reported. 34 The risk to clients while caring for their pets with cancer or administering cytotoxic drugs also is poorly defined. Some contamination of the environment, and potential exposure to family members or caregivers occurs when people are receiving chemotherapy. 33, 35 Guidelines for safe handling of PO chemotherapeutics in human practice have been compiled, attempting to limit potential harms. 36 In veterinary medicine, some environmental contamination also has been documented, 37 and similar precautions should be taken by clients handling veterinary cancer patients undergoing chemotherapy and administering drugs at home to their pets. 38, 39 Because chemotherapy drugs usually have a low therapeutic index, inappropriate administration increases risks of exposure to personnel, as well as the risk of adverse events for the patient. Evaluation and suggestions in this regard are beyond the scope of this consensus statement, but some guidelines have been included that also impact the safety of those administering drugs. The European consensus statement on chemotherapy use recommends that these drugs should have proven efficacy before administration, recognizing that most are used in an off-label fashion. Acknowledging that practitioners other than oncologists do administer these drugs, at a minimum, consultation with a veterinary oncologist to determine the risks versus benefits to the patient is strongly recommended. The reader is referred to the following resources regarding patient safety: 
| F E DE RA L A ND S T AT E G U ID E LI N ES

| E XP OS U R E R I S K S : GU I DE LI N E S FO R M I TI G AT ION
Exposure to cytotoxic drugs can occur at many time points. For staff, risks occur during handling, preparation, and administration of the drugs.
Pet owners risk exposure when they administer PO medications at home and also when they are exposed to secretions and excreta from their pets. These latter exposure events also are risks to veterinary staff when patients are hospitalized after their treatments or admitted for treatment of adverse events. The routes of exposure include skin contact, skin absorption, inhalation of aerosols or drug particles, ingestion, and needle stick injuries. 41 The guidelines below are currently recommended practices, but they are being continually revised.
| P E RSON N EL TR A I NI N G
In human hospitals, the rate of compliance with chemotherapy safety guidelines varies from 68% to 80%. The attitude of oncology nurses to preventative measures is altered by their education and their belief in the risks posed. 42, 43 Reasons cited for lack of use of PPE include: they are not comfortable, they were forgotten because of work pressures, and they were not believed to be necessary. 44 Complacency occurs with PO medications because people do not perceive them to be as toxic as parenteral medications. 45 Additional concerns in veterinary medicine include increased client costs and the perception that safety practices can decrease efficiency. Although there are costs associated with using appropriate safety equipment, their use does not impede workflow and educated veterinary technical staff are willing to use protective practices. 46 All of the aforementioned obstacles should be considered and addressed during training.
Only trained personnel should handle and administer chemotherapeutics, and training should be documented in staff personnel files and, for owners, in the medical records of the patients being treated, before the handling of any HD. A safety officer should be designated in each facility, with responsibility for training, documentation, and continual review (at least every 6 months) and updating manuals as needed when new guidelines become available.
Written policies and procedures for the safe handling of HD must be in place in any facility in which HD are handled. 47 All employees must be trained on the proper care and use of PPE and spill kits. 47 Workers should be trained to wear proper PPE during HD receiving, storage, preparation, administration, disposal, and in cleaning up waste from patients that have received HD.
PPE Recommendations for preparation, administration, spill and waste management, and inventory management
Proper use of CSTD to ensure containment of HD during compounding and administration and methods of preventing aerosol formation and spread of contamination should be taught. Employees must also understand proper methods of drug transportation within the facility. Policies and procedures regarding drug spills should be established, and employees should understand how to recognize and manage a spill.
Large spills should be handled by workers who are trained in handling 
| EN V I RON M EN T
The environment in chemotherapy safety should be set up so as to limit direct exposure to HD and decrease the risk of indirect exposure by contaminated packaging, poor handling technique, and spills. The risk of exposure starts when HD are delivered to the facility. These drugs should be labeled as HD at entry to the facility to ensure that appropriate safety measures are followed. In testing of vials and packaging of cytotoxic drugs at arrival from the manufacturer, surface contamination is common, ranging from 0% to 100% of vials tested. [49] [50] [51] In 1 study, no contamination of vials had occurred when they arrived from the distributor, but frequent contamination of vials that had been stored in the pharmacy was identified, with a presumption of cross contamination from the preparation areas. 49 In areas receiving chemotherapy agents, such as a central supply facility, staff should, at a minimum, handle incoming drugs from suppliers with chemotherapy-rated gloves to prevent exposure from broken vials. Staff should be trained in how to manage spills and broken vials.
Storage should be carried out according to labeled recommendations (eg, refrigerated, room temperature, light-sensitive). The HD should be stored in a separate, labeled area. Refrigerated items should be stored in a dedicated, labeled refrigerator that is not used to store food or other drugs. In addition, areas in which HD are stored or prepared must be designated and clearly marked with appropriate signage.
Eating, drinking, smoking, chewing gum, using tobacco, applying cosmetics, or storing food or drinks must be prohibited in areas in which HD are stored, prepared, or used. 40 Warning signs should be posted Commercially available CSTD
| P R EP A R AT I O N A N D TR AN S P O R T O F C HE M OTH ER A PY D RU G S
Only personnel trained in the handling of HD and proper technique should prepare chemotherapy drugs. Orders and prescriptions should be independently calculated and verified by at least 2 separate individuals, but ideally including the prescribing clinician, a second person trained in handling HD, and the worker responsible for preparation.
Full PPE should be worn during preparation. A plastic-backed absorbent pad should be placed under the preparation site, and should be replaced at least once daily, or anytime a spill occurs or the pad is contaminated. Only supplies essential to drug preparation should be placed in the BSC to avoid disrupting the efficiency of the BSC. Critical operations should be done at least 3 inches above the work surface.
Splitting, opening, or crushing tablets or capsules should never occur. The worker responsible for transportation should, at a minimum, wear chemotherapy-rated gloves.
| D ECON TA M I N AT ION
Written protocols and supplies for cleaning should be available and readily accessible, and only trained staff should be involved in cleaning.
A spill kit and hazardous waste container should be readily accessible in chemotherapy receiving, preparation, and administration areas, as well as in holding areas for patients receiving chemotherapy. Cleaning supplies used in the chemotherapy area should not be used in nonchemotherapy areas. Dedicated mops, buckets, and cleaning supplies should be identified and used. All surfaces associated with HD handling should be considered contaminated. All equipment, counters, and work surfaces should be cleaned with a deactivating agent and cleaning agent at the start of the day, before and after each activity, and at the end of the work shift.
Because no universal cleaner exists for all chemotherapy drugs, and no specific wipe-down procedures have been studied, no proven decontamination procedures exist. Most commonly used cleaning agents contain some form of detergent and hypochlorite solution.
However, strong detergent and water may remove most drug residues when the directions as indicated on the container are followed. Repetition should provide increased effectiveness of decontamination. The use of alcohol for primary disinfection will not deactivate HD and may result in spread of contamination, although a final alcohol wipe is sometimes used to prevent corrosion of stainless steel surfaces. Directly spraying a surface is not recommended, because of the risk of aerosolization. Gauze, wipes, or paper towels should be sprayed directly, and then used to wipe the surface. Sprayers or pressure washers should not be used for initial cleaning of cages, kennels, or stalls used for housing patients treated with HD. 
0 | D IS POSA L
The EPA has been granted authority to enforce regulations set forth by the RCRA, which tracks hazardous waste from generation to disposal.
The OSHA and ASHP recommend that hazardous waste be disposed of in a manner similar to that required for RCRA (https://www.epa.gov/ rcra/resource-conservation-and-recovery-act-rcra-regulations#haz). All hazardous waste should be disposed of and stored separately from regular waste and according to federal, state, and local regulations. Trace wastes (<3% of original quantity) should be disposed of in chemotherapy waste containers (yellow in the United States). Waste containers should be clearly labeled, leak-proof, and covered with a foot-pedal operated lid to minimize respiratory exposure and contamination.
Puncture-proof containers are needed for sharp or breakable items.
Waste disposal should be carried out by licensed commercial waste disposal companies. After administration, the IV catheter should be removed with lines and tubing intact. The outer glove then should be removed, inside-out, with the IV catheter contained inside the glove. Administration materials should be properly disposed of and decontamination procedures followed. Gowns should not be worn longer than 3 hours to prevent permeation, and then should be removed and discarded after use, or earlier when soiled. Gloves should be discarded after each use and hands washed. 47 
| M A N A GEM E N T OF P A TI EN TS
The duration of excretion of cytotoxic drugs has not been established for most drugs in veterinary patients. Drug might be expected to be Animals receiving chemotherapy should remain in a controlled environment and not be allowed to urinate or defecate in community areas, areas where children may be exposed, or areas that cannot be easily cleaned for at least 48 hours after drug administration. Ideally a low-traffic, sunlit area would be preferred for elimination. If excreta are found in the house, the area should be cleaned, and hands should be washed afterwards.
Recommendations for cleaning excreta include wearing gloves, avoiding high-pressure sprays, and using disposable towels. Solid items should be removed with gloved hands and double-bagged with 
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